- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Embryo Bill Decision Offers Hope to People With MS
—
LONDON, May 19LONDON, May 19 /PRNewswire/ -- The MS Society welcomes the decision by MPs to allow scientists to use 'hybrid' human - animal embryos in research into conditions such as multiple sclerosis (MS).
Jayne Spink, Director of Policy and Research at the MS Society, said: "This really is a victory for common sense.
"Allowing scientists to further explore this avenue of research may prove to be hugely beneficial not just to the 85,000 people with multiple sclerosis (MS), but to the hundreds of thousands of people living with debilitating, degenerative and life limiting conditions.
"The MS Society believes it is essential to keep all possible avenues of research open and supports the use of the best technology available to achieve its goals of finding effective treatments for people with MS."
Notes to Editors:
- The MS Society http://www.mssociety.org.uk) is the UK's largest charity dedicated to supporting everyone whose life is touched by MS, providing respite care, an award-winning freephone helpline (0808-800-8000), specialist MS nurses and funds around 40 vital MS research projects in the UK. - Multiple sclerosis is the most common disabling neurological disorder affecting young adults and an estimated 85,000 people in the UK have MS. - MS is the result of damage to myelin - the protective sheath surrounding nerve fibres of the central nervous system - which interferes with messages between the brain and the body. - For some people, MS is characterised by periods of relapse and remission while for others it has a progressive pattern. - Symptoms range from loss of sight and mobility, fatigue, depression and cognitive problems. There is no cure and few effective treatments.
Related news
Related News
- Renewed Hope for Mild Alzheimer's Patients as NICE Process on Anti-Dementia Medicines Ruled Unfair
- Gates Foundation Welcomes G8 Commitments and Urges Follow Through to Address Problems Affecting the World's Poor
- French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia
- Astonishing 52 percent of Newly Diagnosed Bipolar Disorder Patients Receive Antidepressant Drugs in First-Line Treatment
- Emerging Therapies, Including Bristol-Myers Squibb/Medarex's Ipilimumab, Will Drive Growth in the Malignant Melanoma Drug Market
- Arthritis Society Offers Hope for Sufferers With New Cures - Free Book and Free Supplement
- Unite Calls for Government Decision to Save 700 Fujitsu Redundancies on GBP13bn NHS IT Contract
- WHO Report Says 9.7 Million at Risk of Death from AIDS Today; AHF Renews Call for US Congress to Commit to Scale up Treatment to Seven Million Lives
- Bill Gates Announces US$168 Million to Develop Next-Generation Malaria Vaccine
- Unite Calls for Government Decision to Save Jobs and Skills on GBP13bn NHS IT Contract
Latest News
- Nobel Prize to HPV Researcher Highlights Importance of Cervical Cancer Screening and Prevention
- Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics
- Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
- Grifols Breaks Ground on New IVIG Facility
- Oncalis AG Licenses PI3K Inhibitors From ChemDiv Inc.
- Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA
- Botaneco Receives Natural Ingredient Approval From ECOCERT(R) for Hydresia(TM) G2
- Alcan Packaging Acquires Pharmaceutical Flexible Packaging Facility in India
- Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
- Laborie Medical Technologies Announces Exclusive Distribution Agreement with T-DOC(R), LLC
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us